Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | CNR2 | P34972 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395078 | 0.95 | ALDH1A1 (0.67) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3394420 | 0.95 | ALDH1A1 (0.67) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3395664 | 0.95 | ALDH1A1 (0.67) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL8203698 | 0.95 | ALDH1A1 (0.67) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3397990 | 0.94 | NPSR1 (0.71) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL13400384 | 0.93 | KMT2A (0.64) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3393043 | 0.93 | CHRM2 (0.64) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3398035 | 0.92 | ALDH1A1 (0.72) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3395504 | 0.92 | NPSR1 (0.63) | ALDH1A1CNR1CNR2KMT2AMAOB | |
| SCHEMBL3396934 | 0.92 | ALDH1A1 (0.72) | ALDH1A1CNR1CNR2KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | claimed |
| EP-2074105-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-07-01 | — | — | EP | claimed |
| WO-2008043183-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-04-17 | — | — | WO | claimed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, CACNA1F | ALDH1A1 2138/4885CNR1 164/4885CNR2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.